DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Telcagepant
Telcagepant
Anti-Infectives Industry Over the Next 5 Years and Beyond
Stems for Nonproprietary Drug Names
G Protein-Coupled Receptors
Rimegepant in the Treatment of Migraine
Annexes of the Annual Report 2011
761077Orig1s000
Randomized Controlled Trial of the CGRP Receptor Antagonist Telcagepant for Prevention of Headache in Women with Perimenstrual Migraine
Study Protocol with Amendment 01
CLINICAL REVIEW(S) Clinical Review Laura Jawidzik, MD NDA 211765 Ubrogepant/UBRELVY
Monoclonal CGRP Ligand/Receptor Antibodies for the Preventive Treatment of Episodic and Chronic Migraine
The World's Health Care Crisis
Experiences with Pips and Their Required Revisions on the Critical Path of the Development of Medicines in Indications for Adult Patients
Stembook 2018.Pdf
CGRP and Headache: a Brief Review
Inhibitors & Agonists Compound Screening Libraries
E-Binder March 2020
Differential Inhibitory Response to Telcagepant on Αcgrp Induced
Register for NDO Access
Top View
Viktoria Behse Aus Münster
Silver State Scripts Board Meeting
Endosomal Proteolysis Regulates Calcitonin Generelated Peptide
Florencio Zaragoza Dörwald Lead Optimization for Medicinal Chemists
WO 2018/005695 Al O
Pharmacologic Characterization of ALD403, a Potent Neutralizing Humanized Monoclonal Antibody Against the Calcitonin Gene- Related Peptide
Ubrogepant to Treat Acute Migraine in Adults
South Dakota Department of Social Services
CLINICAL REVIEW(S) Clinical Review Laura Jawidzik, MD NDA (B) (4) and 212728 Rimegepant (B) (4)
CGRP Antagonists for the Treatment of Migraine: Rationale and Clinical Data
Multi-Indication Pricing: Big Hurdles and Actionable Options
WO 2015/127416 Al 27 August 2015 (27.08.2015) P O P C T
CGRP Receptor Antagonism and Migraine
Rxfiles Chart Updates – 11Th Edition – DRUG, Disease, Trials INDEX – Generic Name / TRADE NAME ©
U.S. Pharmaceutical/Biotech Industry Update
Blocking CGRP in Migraine Patients – a Review of Pros and Cons
Anti‐Migraine Calcitonin Gene–Related Peptide Receptor
Online Supplementary Reference List [S1] J. Olesen Et Al., “Calcitonin
Neuropeptide Receptors in Pain Circuitries: Useful Targets for CNS Imaging with Non-Peptide Ligands Suitable for PET?
Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
Therapeutic Effects and Safety of Olcegepant and Telcagepant for Migraine: a Meta-Analysis
Side Effect Profiles
Dilisym Simulations Support the Liver Safety of Ubrogepant in New Toxicological Sciences Publication
WO 2015/120110 A2 13 August 2015 (13.08.2015) P O P C T
1 Supplemental Table 1: Primary Outcome Result Reporting Discrepancies Between Clinicaltrials.Gov (CT.Gov) and Publication
Emerging Drugs for Migraine Treatment: an Update
Onset of Efficacy and Duration of Response of Galcanezumab for The
761077Orig1s000
Small Molecule Calcitonin Gene-Related Peptide Receptor Antagonists for the Acute Treatment of Migraine
2011 Medicines in Development for Women
Meilensteine in Der Therapie Von Migräne Und Kopfschmerz: 35 Jahre Kopfschmerzforschung
Articles Efficacy and Tolerability of MK-0974 (Telcagepant), a New Oral Antagonist of Calcitonin Gene-Related Peptide Receptor
View the PDF Document
CGRP and Headache
Progress in Structure Based Drug Design for G Protein-Coupled Receptors Miles Congreve,* Christopher J
Characterization of Ubrogepant: a Potent and Selective Antagonist of the Human Calcitonin Gene‒Related Peptide Receptor S
E-Binder January 2021
Anti-CGRP Monoclonal Antibodies: a Breakthrough in the Treatment of Migraine
The 'Wise List' – a Comprehensive Concept to Select, Communicate and Achieve Adherence to Recommendations of Essential
Telcagepant for Acute Migraine
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
Merck & Co., Inc.(NYSE: MRK)